Found: 14
Select item for more details and to access through your institution.
Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 8, p. 1684, doi. 10.3390/jcm10081684
- By:
- Publication type:
- Article
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first‐line therapy with hypomethylating agents alone or in combination with Venetoclax.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. E80, doi. 10.1002/ajh.26846
- By:
- Publication type:
- Article
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia–like or acute lymphoblastic leukemia–like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study
- Published in:
- Annals of Hematology, 2023, v. 102, n. 5, p. 1099, doi. 10.1007/s00277-023-05162-0
- By:
- Publication type:
- Article
Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm.
- Published in:
- 2020
- By:
- Publication type:
- Case Study
Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3196, doi. 10.3390/cancers12113196
- By:
- Publication type:
- Article
The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions.
- Published in:
- Bioengineering (Basel), 2023, v. 10, n. 5, p. 591, doi. 10.3390/bioengineering10050591
- By:
- Publication type:
- Article
AML-188: Venetoclax with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S289, doi. 10.1016/S2152-2650(21)01692-X
- By:
- Publication type:
- Article
Poster: AML-188: Venetoclax with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S213, doi. 10.1016/S2152-2650(21)01336-7
- By:
- Publication type:
- Article
Cluster Analysis Identifies a Specific Immunophenotypic Profile Associated with High Risk of Induction Failure and Shorter Survival in NPM1-Mutated AML.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S217, doi. 10.1016/j.clml.2019.07.089
- By:
- Publication type:
- Article
Detection of Leukemia-Associated Immunophenotypic Profiles at Variable Frequencies in Healthy Donors Bone Marrow Specimens.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S281, doi. 10.1016/j.clml.2017.07.063
- By:
- Publication type:
- Article
MRD Status and its Prognostic Significance in High-Risk AML Patients: A Single Center Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S278, doi. 10.1016/j.clml.2017.07.058
- By:
- Publication type:
- Article
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 5, p. 1, doi. 10.1002/hon.3310
- By:
- Publication type:
- Article
Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 11, p. 1304, doi. 10.1002/ajh.25942
- By:
- Publication type:
- Article
A case of disseminated blastic plasmocytoid dendritic cell neoplasm.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 11, p. 1433, doi. 10.1002/ajh.25109
- By:
- Publication type:
- Article